Targeted Oncology1d
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Monthly Prescribing Reference1d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Tempest Therapeutics granted FTD from FDA for amezalpat
Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...
Cancer Therapy Advisor1d
Amezalpat Gets Fast Track Designation for HCC
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Nasdaq1mon
Tempest Therapeutics Receives FDA Orphan Drug Designation for Amezalpat in Hepatocellular Carcinoma Treatment
Tempest Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation to amezalpat (TPST-1120), a selective PPAR⍺ antagonist, for treating hepatocellular carcinoma (HCC), which ...
Hosted on MSN7mon
Tempest falls after new trial data for liver cancer therapy
Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...
Hosted on MSN1mon
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor alpha (PPAR-α) antagonist ...